Sosei Builds APAC Independence Through Idorsia Deal

Japan Commercial Infrastructure

Sosei Heptares' acquisition of Idorsia's ex-China APAC operations will give the Japan-UK group ready-made independent development and commercialization capabilities in Japan, accelerating by "five to 10 years" its goals in its home market, its CEO tells Scrip. The deal also brings a marketed drug and options to selected Idorsia pipeline assets. 

The acquisition deal will double the size of Sosei Group.
The acquisition deal will double the size of Sosei Group. • Source: Shutterstock

Sosei Group Corp. has acquired Swiss firm Idorsia Ltd.’s operating businesses in Japan and the Asia Pacific region, excluding China, for CHF400m ($466m), providing the Japan-UK group with ready-to-use development and commercialization capabilities in its home market.

More from Japan

Japan T-Reg Venture RegCell Raises New Funds, Relocates To US

 
• By 

Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.

Eisai Expands Dementia Ecosystem Via EcoNaviSta Acquisition

 
• By 

Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.

Multiple Factors Behind Accelerating Private Equity Plays In Japan, APAC

 

With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.

Novartis Joins MRGPRX2 Race Through $800m+ Kyorin Deal

 
• By 

Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.

More from Focus On Asia

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By 

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

Mounjaro In India: Price Differential, Window Of Opportunity

 

Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?

LigaChem Eyes Future Acquisition Of IKSUDA Following 26.6% Stake

 
• By 

South Korea's LigaChem is kickstarting a growth and globalization drive through a potential future acquisition of UK ADC player IKSUDA.